<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in children: Complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in children: Complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in children: Complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ruth A McDonald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Advances in immunosuppressive therapy and post-transplant management have led to improvements in both graft and patient survival in pediatric kidney transplant recipients. However, long-term success has been limited by complications due to immunosuppression, rejection, and recurrent disease.</p><p>This topic will provide an overview of the complications of kidney transplantation in children. Some complications of kidney transplantation are unique to children, while others are observed in all transplant recipients. Additional issues concerning transplantation in children and issues in kidney transplantation common to both children and adults are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/6120.html" rel="external">"Kidney transplantation in children: General principles"</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GRAFT DYSFUNCTION</span></p><p class="headingAnchor" id="H910884511"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The causes of kidney allograft dysfunction vary with the time after transplantation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate</strong> (zero to one week postsurgery) – Causes of <strong>delayed graft function</strong> (immediate kidney failure persisting after transplantation) include postischemic acute kidney injury, vascular thrombosis of the renal artery or vein, urologic complications (ie, urinary leak or obstruction), and rarely, hyperacute rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early</strong> (1 to 12 weeks postsurgery) – Among patients with initial graft function who develop early kidney insufficiency (ie, 1 to 12 weeks post-transplantation), the major causes of graft dysfunction are acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, infection, hypovolemia, and recurrent disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late acute</strong> (after three months) – Allograft dysfunction that acutely develops more than three months after transplantation is most commonly due to acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, hypovolemia, pyelonephritis, and recurrent or de novo kidney disease [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late chronic</strong> (years) – Slowly progressive kidney disease that occurs over a period of years after kidney transplantation most commonly results from chronic allograft injury, calcineurin inhibitor nephrotoxicity, hypertensive nephrosclerosis, viral infections, and recurrent or de novo kidney disease.</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Delayed graft function</span><span class="headingEndMark"> — </span>Kidney failure persisting immediately after transplantation is called delayed graft function (DGF). The definition of DGF varies in different studies, but generally refers to oliguria or the requirement for dialysis within the first week post-transplantation [<a href="#rid2">2</a>]. Previously, patients with DGF have had a 15 to 25 percent lower graft survival rate than those without DGF.</p><p>The major causes of DGF in children are the following (see  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Postischemic acute kidney injury is the most common cause of DGF</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis or embolization of the renal artery or vein</p><p class="bulletIndent1"><span class="glyph">●</span>Accelerated rejection superimposed on ischemic acute tubular necrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Urologic abnormalities (ie, urinary leak or hematoma)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperacute rejection (generally preventable) due to preformed anti-human leukocyte antigen (HLA) antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Factors related to the donor (ie, cardiovascular instability, older donor age, kidney function based on serum/plasma creatinine)</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Acute kidney injury</span><span class="headingEndMark"> — </span>Several factors may be responsible for postischemic acute kidney injury. These include the age and condition of the donor, specific recovery procedure, technique of organ preservation, adequacy of volume replacement during and after surgery, and the cold and warm ischemia times. Tubular damage may be aggravated by the use of <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>. There is evidence that the addition of <a class="drug drug_pediatric" data-topicid="12761" href="/d/drug information/12761.html" rel="external">sirolimus</a> in combination with either cyclosporine or tacrolimus prolongs DGF. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Vascular thrombosis</span><span class="headingEndMark"> — </span>Vascular thrombosis of the renal artery or vein is a common cause of graft failure in children receiving kidney transplants. The main risk for thrombosis is an extremely young donor or recipient. Other risk factors include hypercoagulability (such as that due to chronic nephrotic syndrome) and venous malformation in the recipient, pretransplant peritoneal dialysis, a hypotensive episode during or after surgery, the presence of multiple arteries, and bench surgery of graft vessels [<a href="#rid3">3</a>]. Although vascular thrombosis is usually observed within the first few days following transplantation, it can be seen as late as three weeks post-transplant.</p><p>The use of interleukin 2 receptor antagonists may be associated with a decreased risk of graft thrombosis. This was shown in a retrospective study of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) database of transplant patients between 1998 and 2004 in which the incidence of thrombosis was significantly lower among those who received such antibodies (1.07 versus 2.4 percent) [<a href="#rid4">4</a>].</p><p>Other measures that may reduce the incidence of vascular thrombosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Careful hemodynamic monitoring of central venous pressure to ensure adequate allograft perfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consideration of screening for inherited and acquired thrombophilic risk factors, especially if there is a family history or previous episode of thrombosis. Screening is currently available for protein C, S or antithrombin III deficiency, factor V Leiden, prothrombin gene mutations, and the presence of antiphospholipid antibodies. Prophylactic therapy with heparin, low-molecular-weight heparin, and/or <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a> to prevent thrombosis for those with an increased risk of thrombophilia has been successful in preventing graft loss [<a href="#rid5">5</a>]. In some centers, low-molecular-weight heparin is used prophylactically in all pediatric kidney transplant recipients [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/5920.html" rel="external">"Thrombophilia testing in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Correction of vascular depletion related to nephrotic syndrome [<a href="#rid7">7,8</a>].</p><p></p><p>In a study of kidney transplants performed in patients &lt;19 years of age between 1995 and 2014 from the United States Renal Data System, the incidence of allograft loss due to renal vein thrombosis has decreased [<a href="#rid9">9</a>]. However, the cause of improvement could not be ascertained, due to limitations of information within the database.</p><p class="headingAnchor" id="H6"><span class="h3">Urologic complications</span><span class="headingEndMark"> — </span>Early post-transplant urologic complications include [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary leak due to ureteral necrosis, bladder injury, or obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract obstruction, most often due to clots in the urinary tract, postoperative edema, or surgical complication. It is detected as hydronephrosis by kidney ultrasonography. (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a> and <a class="local">'Surgical and urologic sequelae'</a> below.)</p><p></p><p>Although ureteral stents have been proposed as a measure to reduce these complications, their efficacy remains uncertain. In one trial, the use of a ureteral stent at kidney transplantation significantly decreased urinary leak and obstruction with a reduction in overall medical costs [<a href="#rid11">11</a>]. In contrast, a retrospective study found no difference in graft survival and the risk of urinary leakage and ureteral stenosis between patients who had stent placement and those who did not [<a href="#rid12">12</a>]. In this report, stent placement also resulted in additional costs. Both studies demonstrated an increased risk of urinary tract infections with stent placement, especially if the stent remained in place beyond 30 days after transplant [<a href="#rid11">11,12</a>].</p><p>At our institution, stents are used in recipients who have bladder abnormalities with increased risk of urinary retention or high pressure, as well as when the transplant surgeon has concerns about the donor ureter. Our policy is to remove stents before the fourth week post-transplant. (See <a class="local">'Surgical and urologic sequelae'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h3">Hyperacute rejection</span><span class="headingEndMark"> — </span>Hyperacute rejection occurring within the first minutes following transplantation results from preformed host anti-HLA antibodies that bind to vascular endothelial cells of the graft, resulting in activation of the complement cascade and endothelial injury. Neutrophils, macrophages, and platelets are attracted to the antibody binding site and cause further cellular damage. Platelet aggregation on the damaged endothelium leads to fibrin deposition and vascular thrombosis [<a href="#rid13">13</a>]. There are also reports of hyperacute rejection associated with antiendothelial antibodies [<a href="#rid14">14</a>], which are not detected using standard crossmatch methods using donor lymphocytes.</p><p>Approximately 20 percent of children awaiting transplantation have panel-reactive anti-HLA antibodies (PRA) &gt;80 percent [<a href="#rid15">15</a>]. However, only 3 percent of the children who received a kidney transplant between 2010 and 2012 in the United States had a PRA &gt;80 percent [<a href="#rid16">16</a>]. Sensitization occurs following blood transfusions, pregnancies, and transplantation. (See  <a class="medical medical_review" href="/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>.)</p><p>Desensitization protocols have included high-dose intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a>, plasmapheresis, and <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a>, although there are no controlled studies in children [<a href="#rid17">17</a>]. Nationwide programs are needed to find fully compatible kidneys for each pediatric recipient [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Pretransplant HLA desensitization'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Acute rejection</span><span class="headingEndMark"> — </span>Acute kidney allograft rejection is a frequent complication of pediatric kidney recipients, which may occur several days, weeks, or months after transplantation. It is defined as an acute deterioration in allograft function, generally detected by an elevation in the serum creatinine level, which is associated with specific pathologic changes in the graft obtained via an allograft biopsy. The two principal histologic forms of rejection are acute T cell mediated cellular rejection and acute antibody-mediated rejection, which are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p>In children with kidney transplants, the rate of acute rejection has decreased over the past 30 years [<a href="#rid19">19</a>]. This decrease in the incidence of acute rejection appears to be due to the introduction of newer immunosuppressive agents [<a href="#rid20">20</a>]. Based on the NAPRTCS data, hospitalization within the first 24 months following transplantation is more frequently caused by post-transplant infections than acute rejection [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical signs</strong> – The classic signs of acute rejection, such as fever and graft tenderness, are observed less commonly with current immunosuppressive regimens. With these newer regimens, acute rejection episodes are often only detected by a rise in the serum concentration of creatinine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal biopsy confirmation</strong> – Acute rejection is confirmed histologically via kidney biopsy, a technique that can be performed with minimal risk in children [<a href="#rid21">21,22</a>]. In the case of a small pediatric recipient of an adult-sized kidney, rejection may be present with no or only a small elevation in serum creatinine. In this setting, kidney biopsy may be considered earlier when the results of the serum creatinine levels are equivocal.</p><p></p><p class="bulletIndent2">There is ongoing debate on the role of protocol biopsy in children to detect subclinical rejection, assess response to therapy for rejection, and surveillance for chronic allograft nephropathy [<a href="#rid23">23,24</a>]. It remains to be demonstrated whether graft survival is improved by detecting these histologic changes, as suggested by results in adult patients. (See  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for acute rejection</strong> – Among stable pediatric allograft recipients, the following strategy relating to the timing of serum creatinine concentration measurement is recommended [<a href="#rid25">25</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Daily measurement during the first two weeks</p><p class="bulletIndent2"><span class="glyph">•</span>Twice to three times a week two to four weeks after transplantation</p><p class="bulletIndent2"><span class="glyph">•</span>Twice per week during the second month</p><p class="bulletIndent2"><span class="glyph">•</span>Weekly from the third to fourth month</p><p class="bulletIndent2"><span class="glyph">•</span>Twice a month from the fifth to eight months</p><p class="bulletIndent2"><span class="glyph">•</span>Monthly after the eighth month post-transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The following conditions may also present with an elevation in serum creatinine and need to be distinguished from acute rejection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urinary tract obstruction</strong> (generally ureteral obstruction) is differentiated from acute rejection by an ultrasound finding of hydronephrosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcineurin inhibitor (CNI) nephrotoxicity</strong> is differentiated from acute rejection by kidney biopsy and/or a positive response of deceasing serum creatinine with lowering of CNI dose</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytomegalovirus (CMV) and BK polyomavirus (BKPyV)</strong> may cause graft dysfunction (see <a class="local">'Viral infections'</a> below and  <a class="medical medical_review" href="/d/html/105281.html" rel="external">"Prevention of cytomegalovirus disease in kidney transplant recipients", section on 'Impact on graft function and mortality'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal artery stenosis</strong> is an uncommon complication and is differentiated from acute rejection by imaging studies (see  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension", section on 'Diagnostic test options'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pyelonephritis</strong> may occur, especially in children with abnormal urinary tracts, and may present with fever, abdominal pain, and decreased graft function</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Chronic allograft injury</span><span class="headingEndMark"> — </span>Similar to adults, the most common reported cause of graft loss after the first year among transplant recipients in children is chronic allograft injury (also known as chronic allograft nephropathy). This is a poorly understood disorder, and the etiology remains unknown. The revised 2005 Banff classification system renamed chronic allograft nephropathy to "interstitial fibrosis and tubular atrophy, without evidence of any specific etiology" because the terminology chronic allograft nephropathy was thought to discourage attempts to elucidate the underlying pathogenesis of this entity. (See  <a class="medical medical_review" href="/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy", section on 'Evaluation of IF/TA'</a>.)</p><p>In general, the clinical diagnosis is suggested by the gradual deterioration of graft function as manifested by a slowly rising serum/plasma creatinine concentration, increasing proteinuria (occasionally causing nephrotic range proteinuria), and worsening hypertension. It occurs at least three months post-transplant in the absence of acute rejection, drug toxicity (principally calcineurin inhibitors), or other nephrologic diseases.</p><p>In a pediatric case series of 289 kidney allografts, the risk factors for chronic allograft injury included at least one previous episode of acute rejection and the administration of low doses of <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> [<a href="#rid26">26</a>]. Kidney histology of biopsy samples reveals vascular proliferation of smooth-muscle cells, interstitial fibrosis, tubular atrophy, and glomerular sclerosis [<a href="#rid27">27,28</a>].</p><p>Multiple immunologic and nonimmunologic factors appear to contribute to the pathogenesis of this entity and are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Calcineurin inhibitor toxicity</span><span class="headingEndMark"> — </span>Following kidney transplantation, CNI (<a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>) nephrotoxicity can either be acute (which is largely reversible with reduction in dosing) or progress to chronic kidney disease (which is not reversible). (See  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p>De novo post-transplant thrombotic microangiopathy may be associated with the use of <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>, and <a class="drug drug_pediatric" data-topicid="12761" href="/d/drug information/12761.html" rel="external">sirolimus</a> [<a href="#rid29">29-31</a>]. Although it can be difficult to treat, in some cases, withdrawing the offending agent may lead to resolution of thrombotic microangiopathy. (See  <a class="medical medical_review" href="/d/html/7350.html" rel="external">"Thrombotic microangiopathy after kidney transplantation", section on 'Epidemiology of de novo TMA'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Nonadherence</span><span class="headingEndMark"> — </span>Nonadherence with immunosuppressive medications is an important contributing factor for graft failure [<a href="#rid32">32</a>]. The reported incidence of pediatric graft failure due to nonadherence ranges between 10 to 15 percent, although this rate of incidence is likely to be underestimated [<a href="#rid33">33,34</a>]. Rates of 5 to 50 percent have been reported [<a href="#rid35">35</a>]. Nonadherence correlates with poor outcome in patients with kidney transplants [<a href="#rid36">36</a>].</p><p>Several studies have shown a high incidence of nonadherence, particularly among adolescents and young adults [<a href="#rid37">37-41</a>]. A meta-analysis of medical regimen adherence in pediatric solid organ transplantation found that nonadherence to clinic appointments and tests was most prevalent, at 12.9 cases per 100 patients per year, followed by nonadherence to immunosuppression at 6 cases per 100 patients per year [<a href="#rid42">42</a>]. Poorer adherence was more likely in older patients and in those with a poorer psychological status and family dysfunction.</p><p>Adherence may be an issue when patients are transferred to an adult service. As a result, transition should be prepared in advance by both the pediatric and adult teams and individualized for each patient [<a href="#rid43">43,44</a>].</p><p>Educational and counseling programs can improve medical regimen adherence, which has the potential to improve graft survival [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Recurrence of primary disease</span><span class="headingEndMark"> — </span>In most pediatric series, recurrence of primary disease is responsible for kidney allograft failure in 5 to 15 percent of cases [<a href="#rid19">19,46,47</a>]. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) database, the overall graft failure rate due to recurrent disease is approximately 8 percent [<a href="#rid48">48</a>]. Among the glomerular diseases that may recur in the graft, the most frequent is focal segmental glomerular sclerosis (FSGS) [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Focal segmental glomerulosclerosis</span><span class="headingEndMark"> — </span>Steroid-resistant idiopathic nephrotic syndrome due to primary FSGS accounts for 12 percent of the primary diagnoses of children undergoing kidney transplantation [<a href="#rid19">19</a>]. The overall risk of recurrence of nephrotic syndrome after transplantation is estimated to be approximately 30 percent [<a href="#rid50">50</a>]. FSGS is the most frequent cause of graft loss due to recurrent disease [<a href="#rid49">49,51</a>]. Recurrence of FSGS enhances the risk of allograft loss and is associated with an increased incidence of delayed graft function and acute rejection. Recurrence most often occurs within the first few days after transplantation. In patients with a first graft lost to recurrent disease, the recurrence rate is approximately 80 percent in a subsequent graft.</p><p>(See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>.)</p><p>The risk of recurrence with FSGS is greater in children than adults [<a href="#rid52">52,53</a>]. Risk factors for recurrence in children include:</p><p class="bulletIndent1"><span class="glyph">●</span>Age of primary disease and progression of disease – Recurrence is more frequent when the disease begins after the age of six years and there is a rapid progression to end-stage kidney disease (ESKD). In most series, the disease recurs in one-half of patients when the duration of disease has been shorter than three years [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histology of primary disease - The histopathologic pattern observed in the first biopsy of the original disease is also an important predictive factor of disease recurrence. Recurrence occurs in 50 to 80 percent of patients in whom the initial biopsy reveals diffuse mesangial proliferation (suggestive of more rapidly progressive disease) but in only 25 percent of patients with minimal change disease [<a href="#rid52">52,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying gene variant – Patients with FSGS due to mutations in genes encoding podocyte proteins appear to have a very low risk of recurring disease after kidney transplantation [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial steroid response – Initial steroid resistance of the primary disease is predictive of post-transplant disease recurrence [<a href="#rid57">57</a>].</p><p></p><p>Treatment remains controversial and is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Membranoproliferative glomerulonephritis</span><span class="headingEndMark"> — </span>The risk of recurrent disease is high in pediatric kidney allograft recipients with a primary diagnosis of membranoproliferative glomerulonephritis (MPGN).</p><p>The literature that describes recurrence of MPGN is based on ultrastructural features observed by electron microscopy (EM), which classifies MPGN into subtypes I, II, and III. This classification system has been supplanted by one that uses immune complex and C3 deposition to describe primary MPGN. (See  <a class="medical medical_review" href="/d/html/7343.html" rel="external">"Membranoproliferative glomerulonephritis: Recurrence of idiopathic disease after transplantation", section on 'Classification and pathogenesis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In children, MPGN type I is the primary diagnosis in approximately 2 percent of pediatric kidney transplants [<a href="#rid19">19</a>] and the rate of recurrence (approximately 20 to 30 percent) appears to be higher than that reported in adult patients [<a href="#rid58">58</a>]. Despite the risk of recurrence, graft survival is comparable to that of patients with other causes of kidney failure [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent disease is a major contributor to poor graft survival for patients with MPGN type II [<a href="#rid51">51,59</a>]. Data from the NAPRTCS registry showed that MPGN type II was less common than MPGN type I as a primary diagnosis (0.8 percent) [<a href="#rid19">19</a>], however, the rate of recurrent disease was approximately 45 percent [<a href="#rid59">59</a>]. In this cohort of patients, the five-year graft survival was poor (50 percent), and 15 percent of graft failure was directly due to disease recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MPGN III is a rare primary cause of ESKD in children, and there are no accurate data on its recurrence rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 43 patients with MPGN who received a kidney transplantation, recurrence occurred in 21 (43 percent); younger age at diagnosis and the presence of crescents on initial biopsy were independently associated with recurrence, suggesting that the risk of recurrence is more related to the severity of glomerular changes than MPGN type [<a href="#rid60">60</a>].</p><p></p><p>In patients with both recurrent MPGN I and II disease, no successful therapeutic intervention has been identified. (See  <a class="medical medical_review" href="/d/html/7343.html" rel="external">"Membranoproliferative glomerulonephritis: Recurrence of idiopathic disease after transplantation", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Hemolytic uremic syndrome</span><span class="headingEndMark"> — </span>In children with hemolytic uremic syndrome (HUS), the risk of post-transplant recurrent disease varies depending upon the underlying cause of the primary disease.</p><p class="bulletIndent1"><span class="glyph">●</span>In children with <strong>Shiga-like toxin associated or typical HUS</strong> generally caused by infection with Shiga-toxin producing <em>Escherichia</em> <em>coli</em>, the risk of post-transplant recurrence is less than 1 percent [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Long-term outcome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, the recurrence risk in <strong>non-Shiga-like associated (atypical) HUS</strong> is higher, especially in those with genetic causes of HUS [<a href="#rid61">61,62</a>]. In particular, mutations that result in dysregulation of the complement system are associated with a 50 to 80 percent recurrence rate, and graft failure occurs in 90 percent of those with recurrent disease [<a href="#rid63">63</a>]. There is good evidence that <a class="drug drug_pediatric" data-topicid="109480" href="/d/drug information/109480.html" rel="external">eculizumab</a> therapy (a humanized monoclonal antibody to C5) prevents recurrence of disease in both pediatric and adult patients with complement-mediated HUS due to gene mutations to complement factors H, I, and C3. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Kidney transplantation'</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Primary hyperoxaluria</span><span class="headingEndMark"> — </span>In patients with primary hyperoxaluria, recurrence of oxalate deposits in the graft is constant, leading most commonly to graft failure. In children, the best approach to prevent systemic oxalosis is combined liver and kidney transplantation or chronic <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">pyridoxine</a> treatment in the sub-group of patients who are pyridoxine-responsive [<a href="#rid64">64</a>]. Although most of the experience has been with simultaneous liver/kidney transplant when the patient has ESKD, there also has been reported success with preemptive liver transplant before the development of ESKD, thus delaying or avoiding the need for kidney transplant. (See  <a class="medical medical_review" href="/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Management'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Other diseases</span><span class="headingEndMark"> — </span>For the following primary kidney disorders, the recurrence rate is either not clinically significant or unknown:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Membranous nephropathy</strong> – Membranous nephropathy is a rare cause of ESKD in children, and its recurrence rate is unknown [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin A (IgA) nephropathy</strong> – In patients with IgA nephropathy and IgA vasculitis (Henoch-Schönlein purpura) nephritis, the recurrence of IgA deposits in the graft is very common, but clinically relevant disease is infrequent [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/7344.html" rel="external">"IgA nephropathy: Recurrence after transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus nephritis</strong> – Lupus nephritis is the primary cause of ESKD in 1.5 percent of children undergoing kidney transplantation in North America [<a href="#rid19">19</a>], and more than 10 percent of children with lupus nephritis progress to ESKD [<a href="#rid65">65</a>]. However, recurrence of lupus nephritis in the transplanted kidney is rare. (See  <a class="medical medical_review" href="/d/html/3066.html" rel="external">"Kidney transplantation in adults: Issues related to lupus nephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wilms tumor</strong> – In patients with Wilms tumor, the risk of recurrence or metastasis is negligible after two years of complete remission [<a href="#rid66">66</a>]. Kidney transplantation can, therefore, be performed safely after this period.</p><p></p><p class="headingAnchor" id="H18"><span class="h1">OTHER COMPLICATIONS</span><span class="headingEndMark"> — </span>Although several complications of kidney transplantation usually do not present with graft dysfunction, there are risk factors that may contribute to allograft injury and dysfunction. These include hypertension, infection, diabetes mellitus, anemia, and urologic complications.</p><p class="headingAnchor" id="H19"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is common after kidney transplantation in children. During the first month following transplantation, it occurs in 80 and 60 percent of recipients of allografts from deceased and living related donors, respectively [<a href="#rid67">67</a>]. The incidence decreases over time. In children, post-transplant hypertension is associated with an increased risk of chronic allograft injury, decreased allograft survival, cardiovascular complications, encephalopathy, neurologic sequelae, and mortality [<a href="#rid68">68-71</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Causes</span><span class="headingEndMark"> — </span>The causes of hypertension vary with the time after transplantation.</p><p class="bulletIndent1"><span class="glyph">●</span>During the early postoperative period, elevated blood pressure may be due to fluid overload, acute rejection, or adverse effect of specific immunosuppressive agents (eg, corticosteroids and calcineurin inhibitors [CNIs]) [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After this period, the main causes of hypertension are the administration of corticosteroids and/or CNIs, renal artery stenosis, hypoperfused end-stage native kidneys or failed prior allografts, recurrence of primary disease, and urinary tract obstruction [<a href="#rid67">67</a>].</p><p></p><p>In some cases, obesity may contribute to hypertension. In a multicenter retrospective study of 234 pediatric kidney transplant recipients, the prevalence of metabolic syndrome (ie, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension) increased from 19 to 37 percent from the time of transplant to one-year post-transplant [<a href="#rid74">74</a>]. Left ventricular hypertrophy detected by echocardiogram at one-year post-transplant was more common in patients with metabolic syndrome compared with those without (55 versus 32 percent).</p><p class="headingAnchor" id="H21"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Therapy for post-transplant hypertension initially begins with the administration of antihypertensive agents, even if a correctable cause is present. In our center, we tailor our pharmacologic therapy based on the underlying cause for each individual patient. Angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers are the two most common classes of antihypertensives used in children post-transplant; however, there are no clinical trials comparing different classes of medications regarding BP control and kidney survival [<a href="#rid75">75</a>]. ACE inhibitors and angiotensin receptor blockers should be used with caution, particularly if renal artery stenosis is suspected following ultrasound/Doppler examination. In such cases, angiography should be done and, if indicated, angioplasty may be successfully performed [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Management approach'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Children with end-stage kidney disease (ESKD) are at increased risk for developing cardiovascular disease [<a href="#rid77">77</a>]. The risk factors that lead to atherosclerosis including dyslipidemia and hypertension and their management are similar to those in the general  (<a class="graphic graphic_algorithm graphicRef106010" href="/d/graphic/106010.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/d/html/5753.html" rel="external">"Overview of the management of the child or adolescent at risk for atherosclerosis"</a>.)</p><p>After transplantation, these (hypertension and dyslipidemia) and additional risk factors (eg, diabetes mellitus, hyperhomocysteinemia, and overweight) are exacerbated by the immunosuppressive drugs administered to prevent allograft rejection [<a href="#rid78">78-80</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>CNIs are associated with hypertension and hyperhomocysteinemia</p><p class="bulletIndent1"><span class="glyph">●</span>Mammalian (mechanistic) target of rapamycin (mTOR) inhibitors including rapamycin is associated with dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Corticosteroids are associated with hypertriglyceridemia, hypertension, increased body mass index, and diabetes mellitus</p><p></p><p>Changes in immunosuppressive protocols may reduce the risk of cardiovascular disease. This was illustrated by a study from the Cooperative European Paediatric Kidney transplant Initiative (CERTAIN) registry that reported that the use of <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> and <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil was associated with significantly lower concentrations of all lipid parameters compared with a regimen containing <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and mTOR inhibitors [<a href="#rid81">81</a>].</p><p>In adult kidney transplant recipients, cardiovascular disease is the most common cause of mortality. (See  <a class="medical medical_review" href="/d/html/7314.html" rel="external">"Risk factors for cardiovascular disease in the kidney transplant recipient"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Infections are a permanent risk in patients receiving immunosuppressive drugs. Infections now exceed acute rejection as the most common cause for hospitalization following transplantation [<a href="#rid20">20,82</a>]. Infections occur most frequently soon after transplantation (first six months) when the exposure to immunosuppression is at its highest degree [<a href="#rid20">20,83</a>]. Urinary tract infections (UTIs) and pulmonary infections are frequent during the early postoperative period [<a href="#rid82">82</a>].</p><p>Reported risk factors for infection include [<a href="#rid82">82-84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger recipient age</p><p class="bulletIndent1"><span class="glyph">●</span>Use of monoclonal or polyclonal antibody immunosuppressive induction therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Indwelling hardware</p><p class="bulletIndent1"><span class="glyph">●</span>Higher number of human leukocyte antigen (HLA) mismatches</p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> rather than <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> as first anticalcineurin</p><p></p><p>Prophylactic treatment with <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> may prevent UTI and reduce the incidence of infection with Pneumocystis carinii (jirovecii) [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a>.)</p><p class="headingAnchor" id="H90900566"><span class="h3">Urinary tract infection</span><span class="headingEndMark"> — </span>UTI is a common finding post-transplant, especially in patients with a urologic etiology of ESKD [<a href="#rid86">86</a>]. Despite the risk of UTI post-transplantation, we do not use prophylactic antibiotics, but screen recipients by routinely obtaining urine cultures. It is uncertain whether UTI affects graft survival. Data from the United States Renal Data Systems showed children were at greater risk for graft loss after early, but not necessarily late, UTI [<a href="#rid87">87</a>]. However, other reports did not find a deleterious effect of UTI on graft function [<a href="#rid86">86,88</a>]. (See  <a class="medical medical_review" href="/d/html/7298.html" rel="external">"Urinary tract infection in kidney transplant recipients", section on 'Monitoring for asymptomatic bacteriuria'</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Viral infections</span><span class="headingEndMark"> — </span>Viral infections are common [<a href="#rid89">89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus (CMV)</strong> – CMV infection may present as a primary infection in seronegative patients receiving a graft from CMV seropositive donors. It may also occur in seropositive recipients from either reactivation with the same host strain or from reinfection with the donor's strain. Infection may be asymptomatic or may present with fever, leukopenia, thrombocytopenia, pneumonitis, hepatitis, and allograft dysfunction. The incidence of significant clinical disease is higher in seronegative recipients with primary CMV infection. In addition, the disease is often more severe when the patient has been treated with antilymphocyte antibodies.</p><p></p><p class="bulletIndent1">Both oral <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> have been shown to lower the risk of CMV disease and mortality while preserving kidney allograft function [<a href="#rid90">90</a>]. Because of the risk for the patient and for the kidney allograft, prophylactic therapy is recommended for the recipient of a kidney from a seropositive donor. A discussion of the prevention and treatment of CMV infection and/or disease is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/105281.html" rel="external">"Prevention of cytomegalovirus disease in kidney transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella</strong> – In pediatric kidney recipients, varicella infection may be responsible for severe disease including encephalitis, pneumonitis, hepatic dysfunction, and death [<a href="#rid91">91</a>]. A varicella nonimmune pediatric recipient exposed to varicella should receive postexposure prophylaxis within 72 hours of exposure. If clinical symptoms of the disease develops, intravenous <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> should be given and, if administered, <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> or <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil withdrawn. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection"</a>.)</p><p></p><p class="bulletIndent1">Immunization with the live <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a> is recommended prior to transplantation in all children without varicella antibodies. This procedure reduces disease incidence and helps prevents severe disease [<a href="#rid92">92,93</a>]. In one study, varicella infection occurred in 26 of 212 patients (12 percent) who received the vaccine, but in 22 of 49 (45 percent) who had no history of varicella and were not vaccinated [<a href="#rid92">92</a>]. Three deaths due to infection occurred among the nonvaccinated group, but in none of those who were immunized. Data are insufficient to determine whether live viral vaccines should be administered to transplant recipients still on immunosuppression. Small case series have reported that varicella vaccine was administered without complications, but it was not always efficacious [<a href="#rid94">94,95</a>]. In one small study, for example, four of six children who were nonimmune responded with high antibody titers to varicella vaccination [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV)</strong> – Primary infection with EBV is common in the EBV serology negative recipient (R-) who receives an allograft from an EBV serology positive donor (D+) [<a href="#rid96">96</a>]. Reactivation of EBV in a serology positive recipient is more likely to be asymptomatic.</p><p></p><p class="bulletIndent1">In patients with chronic immunosuppression, post-transplant lymphoproliferative disease (PTLD) appears to be due to B cell proliferation induced by infection with EBV. The risk of PTLD is highest in the R- recipient who received an allograft from a D+ donor [<a href="#rid97">97</a>]. Since more infants and young children are R-, more of these patients will develop PTLD. However, once infected with EBV, adolescents are at significantly higher risk to progress to PTLD and have poorer outcomes compared with younger recipients [<a href="#rid98">98</a>]. Reductions in immunosuppression are recommended in this setting and some children will require treatment with <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex virus (HSV)</strong> – The risk of HSV either as primary infection or reactivation depends on the degree of immunosuppression and time after transplant. Both <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> and <a class="drug drug_pediatric" data-topicid="13001" href="/d/drug information/13001.html" rel="external">valacyclovir</a> are effective agents in the treatment of HSV infection. (See  <a class="medical medical_review" href="/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BK polyomavirus (BKPyV)</strong> – BKPyV viral infection is an important cause of allograft dysfunction in pediatric kidney transplant recipients [<a href="#rid99">99-102</a>]. An analysis of the NAPRTCS registry demonstrated a 5 percent incidence of BKPyV-associated nephropathy (BKPyVAN) in kidney recipients [<a href="#rid103">103</a>]. Seronegative patients are at the greatest risk for developing BKPyVAN. The presence of a ureteral stent is associated with an increase in the risk of BKPyVAN [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1">In a small case series of 20 pediatric kidney recipients with BKPyV viremia, children with BKPyVAN presented later, and had higher viral loads and serum creatinine levels compared with those who were viremic without nephropathy [<a href="#rid105">105</a>]. Children with BKPyVAN who remained viremic (ie, persistent + polymerase chain reaction [PCR]) despite reduction of immunosuppression and antiviral treatment with <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> were at greater risk for loss of kidney function.</p><p></p><p class="bulletIndent1">A screening and preemptive strategy similar to the one used in adult kidney recipients appears to be effective in preventing BKPyVAN in pediatric patients [<a href="#rid106">106</a>]. This approach involves monitoring for viremia by PCR, and reducing immunosuppression and/or administration of antiviral agents after the detection of very early systemic infection (+PCR). (See  <a class="medical medical_review" href="/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus (HPV)</strong> – Warts due to HPV are common in pediatric kidney recipients. There have been no randomized controlled studies regarding the use of HPV vaccines in these patients, and so it remains uncertain whether or not this vaccine is immunogenic in the post-transplant, immunosuppressed patient [<a href="#rid107">107</a>]. Until such data are available, HPV vaccine should be administered according to current guidelines to female candidates (ages 9 to 26 years) prior to transplant. (See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Immunosuppressive therapy in kidney transplant recipients is associated with an increased risk of malignancy as illustrated by the following [<a href="#rid108">108-110</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Data from the NAPRTCS registry show an overall malignancy incidence of 2.6 percent [<a href="#rid19">19</a>]. Of the 310 confirmed malignancies, 262 were lymphoproliferative disease (LPD) and 48 were non-LPD. The median time from transplant to malignancy was 14.9 and 33 months for LPD and non-LPD, respectively. The reported incidence of non-LPD malignancies (solid tumors) was 6.7 times greater than in the general pediatric population (72 versus 11 per 100,000 person-years) [<a href="#rid109">109</a>]. The most common non-LPD malignancy was renal cell carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a French retrospective study of 1326 children following solid organ transplantation [<a href="#rid110">110</a>], there was a 6 percent incidence of malignancy following transplantation, and LPD was diagnosed in 80 percent of the tumors. (See  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a> and  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of childhood kidney allograft recipients (n = 289) from the Australian and New Zealand Dialysis and Transplant Registry found an incidence for malignancy of 16.7 percent over a median follow-up period of 13.4 years [<a href="#rid111">111</a>]. In this cohort, nonmelanoma skin cancer was reported in 196 cases, and the most common other malignancies for the remaining patients included LPD, cervical cancer, and melanoma. Of note, the higher incidence of skin cancer in organ transplants in Australia and New Zealand compared with the United States and Europe may be due to greater sun exposure in a predominantly fair-skinned population [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients", section on 'Pediatric transplant recipients'</a>.)</p><p></p><p>Management is discussed elsewhere and includes preventive measures by avoiding excess immunosuppression and a reduction of immunosuppressive therapy for those who develop malignancy. (See  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation", section on 'Reduction in immunosuppression'</a>.)</p><p>Prognosis has improved after a diagnosis of PTLD with patient survival rates of 91 percent at one year and 87 percent at five years after the diagnosis and graft survival rates of 82 percent at one year and 65 percent at five years [<a href="#rid113">113</a>].</p><p>Other malignancies include skin cancers, renal cell carcinoma, thyroid papillary carcinoma, and ovarian seminoma [<a href="#rid114">114</a>]. Transitional cell carcinoma and gastric adenocarcinoma have been reported in patients who have undergone bladder augmentation [<a href="#rid115">115,116</a>]. It remains unknown if immunosuppression increases the risk of malignancy in patients with either enterocystoplasty or gastrocystoplasty. Routine ultrasound and endoscopic surveillance are recommended beginning 10 years after the bladder augmentation procedure.</p><p class="headingAnchor" id="H26"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>The incidence of post-transplant diabetes mellitus ranges from 1 to 7 percent [<a href="#rid117">117-119</a>]. Risk factors include exposure to CNIs (particularly <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>) and corticosteroid therapy and Black ancestry [<a href="#rid118">118</a>]. The risk of post-transplant diabetes mellitus is higher in patients with a primary diagnosis of cystinosis [<a href="#rid120">120</a>]. (See  <a class="medical medical_review" href="/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H1328086681"><span class="h2">Mineral bone disorders</span><span class="headingEndMark"> — </span>Mineral bone disorders are due to preexisting renal osteodystrophy at the time of transplantation, and subsequent corticosteroid treatment, and reduced graft function [<a href="#rid121">121</a>]. Other contributory factors include hypophosphatemia due to residual hyperparathyroidism and elevated FGF23 and vitamin D deficiency [<a href="#rid122">122</a>]. Following transplantation, intervention is based on the results assessment for growth, leg deformities, and serum levels of calcium, phosphate, magnesium, alkaline phosphatase, 25-hydroxyvitamin D, and parathyroid hormone [<a href="#rid121">121</a>].</p><p>The clinical features and management of mineral and bone disease are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a> and  <a class="medical medical_review" href="/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Anemia is extremely common among pediatric allograft recipients.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study of 167 such children, the prevalence of anemia was approximately 60 to 80 percent at 6 to 60 months post-transplantation, respectively [<a href="#rid123">123</a>]. In this series of patients, development of anemia was related to multiple factors, including iron deficiency, immunosuppressive therapy, bone disease, and decreased kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A registry analysis of 3669 European pediatric patients reported a significant proportion of the transplant recipients were anemic and the anemia was associated with kidney allograft dysfunction and the type of immunosuppressants used [<a href="#rid124">124</a>]. Higher Hb levels were associated with better graft and patient survival and a decrease risk of hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parvovirus B19 infection has also been reported as a cause of severe anemia in pediatric kidney transplant recipients [<a href="#rid125">125</a>].</p><p></p><p>Treatment of anemia in children with CKD and adults following kidney transplantation are discussed separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Treatment of anemia'</a> and  <a class="medical medical_review" href="/d/html/7330.html" rel="external">"Anemia and the kidney transplant recipient", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Surgical and urologic sequelae</span><span class="headingEndMark"> — </span>Surgical sequelae include intraabdominal, urologic, and vascular complications and are a major cause of graft loss [<a href="#rid126">126,127</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraabdominal</strong> <strong>complications</strong> are more common in children with intraperitoneal transplants and include fluid collections (urinoma, seromas, lymphoceles) requiring surgical drainage and intestinal obstruction [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urologic complications</strong> include vesicoureteral reflux [<a href="#rid128">128,129</a>], urolithiasis [<a href="#rid130">130</a>] and ureteral stricture or obstruction. Ureteral obstruction due to stenosis may occur at the level of the anastomosis or at the pyeloureteral junction when the kidney has been turned by 180 degrees to facilitate vascular anastomosis. In one case series of 526 kidney transplants from a single tertiary center, ureteral obstruction occurred in 8 percent [<a href="#rid131">131</a>]. Posterior urethral valves appeared to be a risk factor for ureteral obstruction, perhaps due to pretransplant bladder ischemia, thickness, and collagen remodeling. Approximately one-half of patients presented within 100 days after kidney transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular</strong> <strong>complications</strong> include vascular (arterial or venous) stricture and thrombosis [<a href="#rid127">127</a>]. The risk of vascular complications is higher in younger patients (less than six years of age), which may lead to graft loss [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bladder dysfunction</strong> is common among patients with posterior urethral valves and meningomyeloceles. It may cause chronic obstruction and be associated with recurrent UTIs. (See  <a class="medical medical_review" href="/d/html/6575.html" rel="external">"Clinical presentation and diagnosis of posterior urethral valves"</a> and  <a class="medical medical_review" href="/d/html/6209.html" rel="external">"Myelomeningocele (spina bifida): Urinary tract complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocele</strong> due to collections of lymph fluid leakage from severed lymphatics that overlie the iliac vessels may result in postobstruction due to urinary tract compression. In one retrospective study, lymphocele was detected in three percent of pediatric recipients transplanted after 2006 [<a href="#rid132">132</a>]. Risk factors associated with lymphocele were age &gt;11 years, male sex, transplant before 2006, body mass index &gt;95 percent, and multiple transplantations. In this series, lymphocele was associated with a 10 percent reduction of one-year graft survival.</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Advances in immunosuppressive therapy and post-transplant management have led to improvements in both graft and patient survival in pediatric kidney transplant recipients. However, long-term success has been limited by complications due to immunosuppression, rejection, and recurrent disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft dysfunction</strong> – Graft dysfunction is a common complication posttransplant, and its etiology vary with the time after transplantation. (See <a class="local">'Graft dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immediate</strong> (zero to one week postsurgery) – Causes of <strong>delayed graft function</strong> (immediate kidney failure persisting after transplantation) include postischemic acute kidney injury, vascular thrombosis of the renal artery or vein, urologic complications (ie, urinary leak or obstruction), and rarely, hyperacute rejection. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early</strong> (1 to 12 weeks postsurgery) – Among patients with initial graft function who develop early kidney insufficiency (ie, 1 to 12 weeks post-transplantation), the major causes of graft dysfunction are acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, infection, hypovolemia, and recurrent disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late acute</strong> (after three months) – Allograft dysfunction that acutely develops more than three months after transplantation is most commonly due to acute allograft rejection, calcineurin inhibitor (CNI) toxicity, urinary obstruction, hypovolemia, pyelonephritis, and recurrent or de novo kidney disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late chronic</strong> (years) – Slowly progressive kidney disease that occurs over a period of years after kidney transplantation most commonly results from chronic allograft injury, CNI nephrotoxicity, hypertensive nephrosclerosis, viral infections, and recurrent or de novo kidney disease. Although chronic allograft injury is the most common cause of graft loss after the first year following transplantation, its underlying cause remains unknown. The diagnosis is suggested by a slowly rising serum Cr, increasing proteinuria, and worsening hypertension. (See <a class="local">'Chronic allograft injury'</a> above and  <a class="medical medical_review" href="/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection</strong> ‒ Acute rejection, a common cause of graft dysfunction in the first year of life (early and late acute presentation), is suggested by an acute elevation in the serum creatinine (Cr) level and is confirmed by histologic findings of acute antibody-mediated and cellular rejection. Serum Cr should be routinely monitored for early detection of acute rejection. (See  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a> and <a class="local">'Acute rejection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNI nephrotoxicity</strong> ‒ CNI nephrotoxicity may occur in the early and late acute phase of graft dysfunction and is the major diagnosis in the differential for acute rejection. CNI nephrotoxicity is largely reversible after dose reduction, but may progress to chronic kidney disease, which is usually irreversible. It is distinguished from acute rejection by kidney biopsy and/or a positive response of deceasing serum creatinine with lowering of CNI dose. (See <a class="local">'Calcineurin inhibitor toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent primary disease</strong> – In children, recurrence of primary disease is responsible for graft failure in 5 to 15 percent of cases. Primary pediatric kidney diseases with a high recurrence rate in the transplanted kidney include focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, genetic forms of hemolytic uremic syndrome, and primary hyperoxaluria. (See <a class="local">'Recurrence of primary disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other complications</strong> – Other complications that occur in pediatric kidney recipients include hypertension, cardiovascular disease, infection, malignancy, diabetes mellitus, mineral bone disease, anemia, and surgical sequelae (eg, urologic and vascular complications). These may contribute to allograft injury and dysfunction. (See <a class="local">'Other complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Alkandari O, Nguyen L, Hebert D, et al. Acute Kidney Injury in Children with Kidney Transplantation. Clin J Am Soc Nephrol 2018; 13:1721.</a></li><li><a class="nounderline abstract_t">Grenda R. Delayed graft function and its management in children. Pediatr Nephrol 2017; 32:1157.</a></li><li><a class="nounderline abstract_t">McDonald RA, Smith JM, Stablein D, Harmon WE. Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003; 7:204.</a></li><li><a class="nounderline abstract_t">Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006; 6:585.</a></li><li><a class="nounderline abstract_t">Kranz B, Vester U, Nadalin S, et al. Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr Transplant 2006; 10:788.</a></li><li><a class="nounderline abstract_t">Broyer M, Gagnadoux MF, Sierro A, et al. Preventive treatment of vascular thrombosis after kidney transplantation in children with low molecular weight heparin. Transplant Proc 1991; 23:1384.</a></li><li><a class="nounderline abstract_t">Kim MS, Stablein D, Harmon WE. Renal transplantation in children with congenital nephrotic syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998; 2:305.</a></li><li><a class="nounderline abstract_t">Salvatierra O Jr, Millan M, Concepcion W. Pediatric renal transplantation with considerations for successful outcomes. Semin Pediatr Surg 2006; 15:208.</a></li><li><a class="nounderline abstract_t">Wang CS, Greenbaum LA, Patzer RE, et al. Renal allograft loss due to renal vascular thrombosis in the US pediatric renal transplantation. Pediatr Nephrol 2019; 34:1545.</a></li><li><a class="nounderline abstract_t">Routh JC, Yu RN, Kozinn SI, et al. Urological complications and vesicoureteral reflux following pediatric kidney transplantation. J Urol 2013; 189:1071.</a></li><li><a class="nounderline abstract_t">Tavakoli A, Surange RS, Pearson RC, et al. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol 2007; 177:2260.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Araya CE, Wadsworth CS, et al. Assessing the value of ureteral stent placement in pediatric kidney transplant recipients. Transplantation 2008; 85:986.</a></li><li><a class="nounderline abstract_t">Salmela KT, von Willebrand EO, Kyllönen LE, et al. Acute vascular rejection in renal transplantation--diagnosis and outcome. Transplantation 1992; 54:858.</a></li><li><a class="nounderline abstract_t">Grandtnerová B, Mäcková N, Hovoricová B, Jahnová E. Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports. Transplant Proc 2008; 40:2422.</a></li><li><a class="nounderline abstract_t">Chaudhuri A, Ozawa M, Everly MJ, et al. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013; 24:655.</a></li><li><a class="nounderline abstract_t">Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant 2014; 14 Suppl 1:11.</a></li><li><a class="nounderline abstract_t">Peruzzi L, Amore A, Coppo R. Challenges in pediatric renal transplantation. World J Transplant 2014; 4:222.</a></li><li><a class="nounderline abstract_t">Dello Strologo L, Murer L, Guzzo I, et al. Renal transplantation in sensitized children and young adults: a nationwide approach. Nephrol Dial Transplant 2017; 32:191.</a></li><li class="breakAll">Emmes. The North American Pediatric Renal Trials and Collaborative Studies 2014 Annual Report. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html (Accessed on October 02, 2015).</li><li><a class="nounderline abstract_t">Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4:384.</a></li><li><a class="nounderline abstract_t">Benfield MR, Herrin J, Feld L, et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67:544.</a></li><li><a class="nounderline abstract_t">Birk PE, Blydt-Hansen TD, Dart AB, et al. Low incidence of adverse events in outpatient pediatric renal allograft biopsies. Pediatr Transplant 2007; 11:196.</a></li><li><a class="nounderline abstract_t">Birk PE, Rush DN. Protocol biopsies should be standard of care for pediatric renal allograft recipients! Pediatr Transplant 2006; 10:760.</a></li><li><a class="nounderline abstract_t">Shapiro R, Starzl TE. Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients. Pediatr Transplant 2006; 10:766.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.</a></li><li><a class="nounderline abstract_t">Guyot C, Nguyen JM, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr Nephrol 1996; 10:723.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.</a></li><li><a class="nounderline abstract_t">Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.</a></li><li><a class="nounderline abstract_t">Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.</a></li><li><a class="nounderline abstract_t">Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16:580.</a></li><li><a class="nounderline abstract_t">Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5:2441.</a></li><li><a class="nounderline abstract_t">Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant. J Am Soc Nephrol 2017; 28:2290.</a></li><li><a class="nounderline abstract_t">Feinstein S, Keich R, Becker-Cohen R, et al. Is noncompliance among adolescent renal transplant recipients inevitable? Pediatrics 2005; 115:969.</a></li><li><a class="nounderline abstract_t">Rianthavorn P, Ettenger RB. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint. Pediatr Transplant 2005; 9:398.</a></li><li><a class="nounderline abstract_t">Smith JM, Ho PL, McDonald RA, North American Pediatric Renal Transplant Cooperative Study. Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:493.</a></li><li><a class="nounderline abstract_t">Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009; 87:711.</a></li><li><a class="nounderline abstract_t">Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 1991; 5:137.</a></li><li><a class="nounderline abstract_t">Meyers KE, Thomson PD, Weiland H. Noncompliance in children and adolescents after renal transplantation. Transplantation 1996; 62:186.</a></li><li><a class="nounderline abstract_t">Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49:374.</a></li><li><a class="nounderline abstract_t">Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant 2009; 9:2497.</a></li><li><a class="nounderline abstract_t">Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9:35.</a></li><li><a class="nounderline abstract_t">Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation 2009; 88:736.</a></li><li><a class="nounderline abstract_t">Watson AR, Harden PN, Ferris ME, et al. Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Kidney Int 2011; 80:704.</a></li><li><a class="nounderline abstract_t">Bell LE, Bartosh SM, Davis CL, et al. Adolescent Transition to Adult Care in Solid Organ Transplantation: a consensus conference report. Am J Transplant 2008; 8:2230.</a></li><li><a class="nounderline abstract_t">Beck DE, Fennell RS, Yost RL, et al. Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants. J Pediatr 1980; 96:1094.</a></li><li><a class="nounderline abstract_t">Cameron JS. Recurrent primary disease and de novo nephritis following renal transplantation. Pediatr Nephrol 1991; 5:412.</a></li><li><a class="nounderline abstract_t">Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24:2097.</a></li><li class="breakAll">NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2008. Available at: https://web.emmes.com/study/ped/announce.htm (Accessed on November 09, 2008).</li><li><a class="nounderline abstract_t">Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.</a></li><li><a class="nounderline abstract_t">Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007; 22:496.</a></li><li><a class="nounderline abstract_t">Van Stralen KJ, Verrina E, Belingheri M, et al. Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. Nephrol Dial Transplant 2013; 28:1031.</a></li><li><a class="nounderline abstract_t">Senggutuvan P, Cameron JS, Hartley RB, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4:21.</a></li><li><a class="nounderline abstract_t">Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.</a></li><li><a class="nounderline abstract_t">Habib R, Hebert D, Gagnadoux MF, Broyer M. Transplantation in idiopathic nephrosis. Transplant Proc 1982; 14:489.</a></li><li><a class="nounderline abstract_t">Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.</a></li><li><a class="nounderline abstract_t">Weber S, Tönshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005; 80:S128.</a></li><li><a class="nounderline abstract_t">Ding WY, Koziell A, McCarthy HJ, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 2014; 25:1342.</a></li><li><a class="nounderline abstract_t">Habib R, Antignac C, Hinglais N, et al. Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1987; 10:198.</a></li><li><a class="nounderline abstract_t">Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:2225.</a></li><li><a class="nounderline abstract_t">Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006; 69:504.</a></li><li><a class="nounderline abstract_t">Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.</a></li><li><a class="nounderline abstract_t">Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76:821.</a></li><li><a class="nounderline abstract_t">Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13:663.</a></li><li><a class="nounderline abstract_t">Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol 2008; 28:152.</a></li><li><a class="nounderline abstract_t">Ruggiero B, Vivarelli M, Gianviti A, et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant 2013; 28:1487.</a></li><li><a class="nounderline abstract_t">Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol 1979; 122:793.</a></li><li><a class="nounderline abstract_t">Broyer M, Guest G, Gagnadoux MF, Beurton D. Hypertension following renal transplantation in children. Pediatr Nephrol 1987; 1:16.</a></li><li><a class="nounderline abstract_t">Baluarte HJ, Gruskin AB, Ingelfinger JR, et al. Analysis of hypertension in children post renal transplantation--a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 1994; 8:570.</a></li><li><a class="nounderline abstract_t">Ingelfinger JA, Brewer ED. Pediatric post-transplant hypertension: a review of current standards of care. Child Nephrol Urol 1992; 12:139.</a></li><li><a class="nounderline abstract_t">Malekzadeh MH, Brennan LP, Payne VC Jr, Fine RN. Hypertension after renal transplantation in children. J Pediatr 1975; 86:370.</a></li><li><a class="nounderline abstract_t">Sorof JM, Sullivan EK, Tejani A, Portman RJ. Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999; 10:1324.</a></li><li><a class="nounderline abstract_t">Curtis JJ. Hypertension after renal transplantation: cyclosporine increases the diagnostic and therapeutic considerations. Am J Kidney Dis 1989; 13:28.</a></li><li><a class="nounderline abstract_t">Luke RG. Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol 1991; 2:S37.</a></li><li><a class="nounderline abstract_t">Wilson AC, Greenbaum LA, Barletta GM, et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant 2010; 14:52.</a></li><li><a class="nounderline abstract_t">Seeman T, Feber J. Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension? Pediatr Nephrol 2021; 36:539.</a></li><li><a class="nounderline abstract_t">McMullin ND, Reidy JF, Koffman CG, et al. The management of renal transplant artery stenosis in children by percutaneous transluminal angioplasty. Transplantation 1992; 53:559.</a></li><li><a class="nounderline abstract_t">Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141:191.</a></li><li><a class="nounderline abstract_t">Borchert-Mörlins B, Thurn D, Schmidt BMW, et al. Factors associated with cardiovascular target organ damage in children after renal transplantation. Pediatr Nephrol 2017; 32:2143.</a></li><li><a class="nounderline abstract_t">Becker-Cohen R, Nir A, Rinat C, et al. Risk factors for cardiovascular disease in children and young adults after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1284.</a></li><li><a class="nounderline abstract_t">Bock ME, Wall L, Dobrec C, et al. Management of dyslipidemia in pediatric renal transplant recipients. Pediatr Nephrol 2021; 36:51.</a></li><li><a class="nounderline abstract_t">Habbig S, Volland R, Krupka K, et al. Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens. Pediatr Transplant 2017; 21.</a></li><li><a class="nounderline abstract_t">Hogan J, Pietrement C, Sellier-Leclerc AL, et al. Infection-related hospitalizations after kidney transplantation in children: incidence, risk factors, and cost. Pediatr Nephrol 2017; 32:2331.</a></li><li><a class="nounderline abstract_t">Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 7:662.</a></li><li><a class="nounderline abstract_t">Yin S, Powell EC, Trainor JL. Serious bacterial infections in febrile outpatient pediatric kidney transplant recipients. Pediatr Infect Dis J 2011; 30:136.</a></li><li><a class="nounderline abstract_t">Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990; 89:255.</a></li><li><a class="nounderline abstract_t">Silva A, Rodig N, Passerotti CP, et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 2010; 184:1462.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007; 2:100.</a></li><li><a class="nounderline abstract_t">Esezobor CI, Nourse P, Gajjar P. Urinary tract infection following kidney transplantation: frequency, risk factors and graft function. Pediatr Nephrol 2012; 27:651.</a></li><li><a class="nounderline abstract_t">McCaffrey J, Bhute VJ, Shenoy M. CMV, EBV, JCV and BKV infection and outcome following kidney transplantation in children initiated on a corticosteroid-minimisation immunosuppressive regimen. Pediatr Nephrol 2021; 36:3229.</a></li><li><a class="nounderline abstract_t">Höcker B, Zencke S, Krupka K, et al. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir. Transplantation 2016; 100:862.</a></li><li><a class="nounderline abstract_t">Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216.</a></li><li><a class="nounderline abstract_t">Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35.</a></li><li><a class="nounderline abstract_t">Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190.</a></li><li><a class="nounderline abstract_t">Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008; 4:254.</a></li><li><a class="nounderline abstract_t">Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005; 9:192.</a></li><li><a class="nounderline abstract_t">Höcker B, Fickenscher H, Delecluse HJ, et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 2013; 56:84.</a></li><li><a class="nounderline abstract_t">McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984.</a></li><li><a class="nounderline abstract_t">Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83:1423.</a></li><li><a class="nounderline abstract_t">Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4:2109.</a></li><li><a class="nounderline abstract_t">Herman J, Van Ranst M, Snoeck R, et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004; 8:485.</a></li><li><a class="nounderline abstract_t">Haysom L, Rosenberg AR, Kainer G, et al. BK viral infection in an Australian pediatric renal transplant population. Pediatr Transplant 2004; 8:480.</a></li><li><a class="nounderline abstract_t">Müller A, Beck B, Theilemann K, et al. Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 2005; 24:778.</a></li><li><a class="nounderline abstract_t">Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2:1037.</a></li><li><a class="nounderline abstract_t">Thomas A, Dropulic LK, Rahman MH, Geetha D. Ureteral stents: a novel risk factor for polyomavirus nephropathy. Transplantation 2007; 84:433.</a></li><li><a class="nounderline abstract_t">Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10:920.</a></li><li><a class="nounderline abstract_t">Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727.</a></li><li><a class="nounderline abstract_t">Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8:9.</a></li><li><a class="nounderline abstract_t">Coutinho HM, Groothoff JW, Offringa M, et al. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 2001; 85:478.</a></li><li><a class="nounderline abstract_t">Smith JM, Martz K, McDonald RA, Harmon WE. Solid tumors following kidney transplantation in children. Pediatr Transplant 2013; 17:726.</a></li><li><a class="nounderline abstract_t">Debray D, Baudouin V, Lacaille F, et al. De novo malignancy after solid organ transplantation in children. Transplant Proc 2009; 41:674.</a></li><li><a class="nounderline abstract_t">Francis A, Johnson DW, Craig JC, Wong G. Incidence and Predictors of Cancer Following Kidney Transplantation in Childhood. Am J Transplant 2017; 17:2650.</a></li><li><a class="nounderline abstract_t">Mittal A, Colegio OR. Skin Cancers in Organ Transplant Recipients. Am J Transplant 2017; 17:2509.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants. Am J Transplant 2011; 11:751.</a></li><li><a class="nounderline abstract_t">Holmberg C, Jalanko H. Long-term effects of paediatric kidney transplantation. Nat Rev Nephrol 2016; 12:301.</a></li><li><a class="nounderline abstract_t">Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.</a></li><li><a class="nounderline abstract_t">Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol 2007; 178:1771.</a></li><li><a class="nounderline abstract_t">Robert JJ, Tete MJ, Crosnier H, Broyer M. [Sugar diabetes after renal transplantation in children]. Ann Pediatr (Paris) 1993; 40:112.</a></li><li><a class="nounderline abstract_t">Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72:1020.</a></li><li><a class="nounderline abstract_t">Burroughs TE, Swindle JP, Salvalaggio PR, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009; 88:367.</a></li><li><a class="nounderline abstract_t">Robert JJ, Tête MJ, Guest G, et al. Diabetes mellitus in patients with infantile cystinosis after renal transplantation. Pediatr Nephrol 1999; 13:524.</a></li><li><a class="nounderline abstract_t">Haffner D, Leifheit-Nestler M. CKD-MBD post kidney transplantation. Pediatr Nephrol 2021; 36:41.</a></li><li><a class="nounderline abstract_t">Haffner D, Schüler U. Metabolic bone disease after renal transplantation. Curr Opin Pediatr 2014; 26:198.</a></li><li><a class="nounderline abstract_t">Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40:1306.</a></li><li><a class="nounderline abstract_t">Krischock LA, van Stralen KJ, Verrina E, et al. Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016; 31:325.</a></li><li><a class="nounderline abstract_t">Pinto V, Grandy J, Zambrano P, et al. Severe anemia from parvovirus b19 infection in pediatric renal transplant recipients: two case reports. Transplant Proc 2008; 40:3261.</a></li><li><a class="nounderline abstract_t">Irtan S, Maisin A, Baudouin V, et al. Renal transplantation in children: critical analysis of age related surgical complications. Pediatr Transplant 2010; 14:512.</a></li><li><a class="nounderline abstract_t">Taher A, Zhu B, Ma S, et al. Intra-abdominal Complications After Pediatric Kidney Transplantation: Incidence and Risk Factors. Transplantation 2019; 103:1234.</a></li><li><a class="nounderline abstract_t">Morrison CD, Shannon R, Rosoklija I, et al. Ureteral Complications of Pediatric Renal Transplantation. J Urol 2019; 201:810.</a></li><li><a class="nounderline abstract_t">Ranchin B, Chapuis F, Dawhara M, et al. Vesicoureteral reflux after kidney transplantation in children. Nephrol Dial Transplant 2000; 15:1852.</a></li><li><a class="nounderline abstract_t">Ma S, Taher A, Zhu B, Durkan AM. Post-renal transplant urolithiasis in children: an increasingly diagnosed complication: a retrospective cohort study. Arch Dis Child 2020; 105:69.</a></li><li><a class="nounderline abstract_t">Smith KM, Windsperger A, Alanee S, et al. Risk factors and treatment success for ureteral obstruction after pediatric renal transplantation. J Urol 2010; 183:317.</a></li><li><a class="nounderline abstract_t">Giuliani S, Gamba P, Kiblawi R, et al. Lymphocele after pediatric kidney transplantation: incidence and risk factors. Pediatr Transplant 2014; 18:720.</a></li></ol></div><div id="topicVersionRevision">Topic 6143 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30242029" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute Kidney Injury in Children with Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27778091" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Delayed graft function and its management in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12756045" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16468970" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032424" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcome after kidney transplantation in children with thrombotic risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846467" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preventive treatment of vascular thrombosis after kidney transplantation in children with low molecular weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084734" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal transplantation in children with congenital nephrotic syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818142" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pediatric renal transplantation with considerations for successful outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31129729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal allograft loss due to renal vascular thrombosis in the US pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022008" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Urological complications and vesicoureteral reflux following pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509336" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408579" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assessing the value of ureteral stent placement in pediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1440853" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute vascular rejection in renal transplantation--diagnosis and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790254" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449533" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The clinical impact of humoral immunity in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373166" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : OPTN/SRTR 2012 Annual Data Report: kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540732" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Challenges in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742824" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal transplantation in sensitized children and young adults: a nationwide approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742824" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal transplantation in sensitized children and young adults: a nationwide approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961991" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071025" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300500" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Low incidence of adverse events in outpatient pediatric renal allograft biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032419" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Protocol biopsies should be standard of care for pediatric renal allograft recipients!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032420" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044969" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8971889" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for chronic rejection in pediatric renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787648" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Histopathologic findings associated with a chronic, progressive decline in renal allograft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377384" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354295" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cyclosporine-associated thrombotic microangiopathy in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14696762" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tacrolimus-associated hemolytic uremic syndrome: a case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162193" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28630231" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Understanding Medication Nonadherence after Kidney Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805372" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Is noncompliance among adolescent renal transplant recipients inevitable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15910399" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453202" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295316" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Quantitative patterns of azathioprine adherence after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025523" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improved cadaveric renal transplant outcome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8755814" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Noncompliance in children and adolescents after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2305467" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Noncompliance in organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681814" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133930" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nonadherence consensus conference summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19741474" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21832978" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18822088" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adolescent Transition to Adult Care in Solid Organ Transplantation: a consensus conference report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989973" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1911114" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recurrent primary disease and de novo nephritis following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247694" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Disease recurrence in paediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247694" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Disease recurrence in paediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1498285" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17186280" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300261" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2206875" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384172" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6217601" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Transplantation in idiopathic nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7027555" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recurrence of focal segmental glomerulosclerosis in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286890" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24511128" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307396" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Glomerular lesions in the transplanted kidney in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888559" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395262" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680331" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501861" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23356914" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18359396" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The primary hyperoxalurias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345627" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lupus nephritis in children and adolescents: results of the Italian Collaborative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/229277" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Renal transplantation for Wilms tumor: report of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153254" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypertension following renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7819003" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Analysis of hypertension in children post renal transplantation--a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1628272" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pediatric post-transplant hypertension: a review of current standards of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1089776" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypertension after renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361872" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2660549" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hypertension after renal transplantation: cyclosporine increases the diagnostic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1932642" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pathophysiology and treatment of posttransplant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19254245" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32060819" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532266" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The management of renal transplant artery stenosis in children by percutaneous transluminal angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183713" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular mortality in children and young adults with end-stage kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28804814" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Factors associated with cardiovascular target organ damage in children after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699360" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk factors for cardiovascular disease in children and young adults after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31897714" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Management of dyslipidemia in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370750" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28744628" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Infection-related hospitalizations after kidney transplantation in children: incidence, risk factors, and cost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17250558" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729790" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Serious bacterial infections in febrile outpatient pediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2118307" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20727542" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699393" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effects of urinary tract infection on outcomes after renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057219" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Urinary tract infection following kidney transplantation: frequency, risk factors and graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33825043" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : CMV, EBV, JCV and BKV infection and outcome following kidney transplantation in children initiated on a corticosteroid-minimisation immunosuppressive regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26736017" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322522" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Varicella in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989334" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Varicella and zoster in children after kidney transplantation: long-term results of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018498" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Attenuated varicella virus vaccine in children with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104888" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787792" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042966" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416737" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565314" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575916" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Polyomavirus nephropathy in pediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367285" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367284" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : BK viral infection in an Australian pediatric renal transplant population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148843" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702713" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17700172" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Ureteral stents: a novel risk factor for polyomavirus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17096758" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908275" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093271" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Update on immunizations in solid organ transplant recipients: what clinicians need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719332" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : De novo malignancy after paediatric renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24164825" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Solid tumors following kidney transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328954" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : De novo malignancy after solid organ transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371054" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Incidence and Predictors of Cancer Following Kidney Transplantation in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556451" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Skin Cancers in Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446977" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26656457" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Long-term effects of paediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371782" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707009" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Tumor in bladder reservoir after gastrocystoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457131" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : [Sugar diabetes after renal transplantation in children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579294" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667939" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452283" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Diabetes mellitus in patients with infantile cystinosis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31858226" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : CKD-MBD post kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24535492" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Metabolic bone disease after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460052" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385862" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19010248" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Severe anemia from parvovirus b19 infection in pediatric renal transplant recipients: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070565" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Renal transplantation in children: critical analysis of age related surgical complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113998" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Intra-abdominal Complications After Pediatric Kidney Transplantation: Incidence and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30195847" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Ureteral Complications of Pediatric Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071977" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Vesicoureteral reflux after kidney transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31243010" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Post-renal transplant urolithiasis in children: an increasingly diagnosed complication: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914663" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Risk factors and treatment success for ureteral obstruction after pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25163815" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Lymphocele after pediatric kidney transplantation: incidence and risk factors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
